Derivatives of indole for the treatment of cancer, viral infections and lung diseases
The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
1. A method for reducing tumor volume or ameliorating cancer in a subject comprising administering to said subject having a cancer selected from leukemia, acute myelogenous leukemia, lymphoma, breast cancer, pancreatic cancer, lung cancer and colon cancer an effective amount of a pharmaceutical composition comprising (E)-3-(2-(5-bromo-1H-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile, (Z)-3-(2-(5-bromo-1H-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile, or pharmaceutically acceptable salts thereof.
2. The method according to claim 1 , wherein said compound is (E)-3-(2-(5-bromo-1H-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 , wherein said compound is (Z)-3-(2-(5-bromo-1H-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 , wherein said pharmaceutical composition further comprises an additional antitumoral drug.
5. The method according to claim 4 , wherein said additional antitumoral drug is selected from the group consisting of an anti-mitotic agent, an inhibitor of topoisomerases I or II, a DNA alkylating agent, an anti-metabolic agent, a kinase inhibitor and/or a therapeutic antibody designed to mediate cytotoxicity against cells of said cancer or to modulate a key biological function of said cells.
6. The method according to claim 1 , wherein said compound is administered in combination with radiotherapy, hyperthermia and/or other antitumoral therapies, or before, simultaneously and/or after surgery.
7. The method according to claim 1 , wherein the cancer is lung cancer.
8. The method according to claim 1 , wherein the cancer is pancreatic cancer.
9. The method according to claim 1 , wherein the cancer is leukemia.
10. The method according to claim 1 , wherein the cancer is acute myelogenous leukemia.
11. The method according to claim 1 , wherein the cancer is lymphoma.
12. The method according to claim 1 , wherein the cancer is breast cancer.
13. The method according to claim 1 , wherein the cancer is colon cancer.
14. The method according to claim 1 , said method reducing tumor volume in said subject.
15. The method according to claim 1 , said method ameliorating cancer in said subject.